Medications for opioid use disorder in professional recovery programs in the United States: Policies and recommendation patterns
Main Authors: | Murchison Morgan L. PharmD, MS, Loera Lindsey J. PharmD, Hill Lucas G. PharmD |
---|---|
Format: | Article |
Language: | English |
Published: |
American Association of Psychiatric Pharmacists
2023-06-01
|
Series: | Mental Health Clinician |
Online Access: | https://theijpt.org/doi/pdf/10.9740/mhc.2023.06.163 |
Similar Items
-
Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids
by: Payal H. Desai, PharmD, BCCCP, et al.
Published: (2021-07-01) -
Prevalence and Risk Factors for Iatrogenic Opioid Withdrawal in Medical Critical Care Patients
by: Marlena A. Fox, PharmD, BCPS, BCCCP, et al.
Published: (2023-05-01) -
Anticonvulsant Effects of Aerial Parts of Extract in Mice: Involvement of Benzodiazepine and Opioid Receptors
by: Amir Rashidian PharmD, PhD, et al.
Published: (2017-10-01) -
Characterization of inpatient care for patients admitted to a psychiatric hospital with a home opioid prescription
by: Kei Takamura, PharmD, BCPS, BCPP, et al.
Published: (2023-03-01) -
Potential role of a pharmacist to enhance medication-related aspects of clinical trials conducted in a dedicated clinical research unit
by: Kimberly A. Redic, PharmD, et al.
Published: (2017-06-01)